Clinical Study
Ambulatory Arterial Stiffness Index Is Higher in Hypertensive Patients with Chronic Kidney Disease

Ronaldo Altenburg Gismondi, 1, 2 Mario Fritsch Neves, 1 Wille Oigman, 1 and Rachel Bregman 3

1 Department of Clinical Medicine, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil
2 Departamento de Clínica Médica, Hospital Universitario Pedro Ernesto, Avenue 28 de Setembro 77, Sala 329, Vila Isabel, 20551-030 Rio de Janeiro, RJ, Brazil
3 Nephrology Division, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Ronaldo Altenburg Gismondi, ronaldogismondi@gmail.com

Received 7 January 2012; Revised 28 February 2012; Accepted 28 February 2012

1. Introduction
Epidemiological and observational studies indicate hypertension as a major cause of chronic kidney disease (CKD) [1]. In fact, hypertension and CKD are strongly connected because hypertension is both a cause and a consequence of CKD [2]. Hypertensive patients with CKD present higher morbidity and mortality rates when compared with those with normal renal function [3, 4]. Additionally, high blood pressure is a predictor of decline of glomerular filtration rate (GFR), and conversely, adequate blood pressure control contributes to preserve renal function [5–7].

Vascular changes are commonly observed in CKD patients, including reduced arterial elasticity observed in patients with end-stage renal disease [8, 9]. Fibroelastic intimal thickening, increased extracellular matrix, enhanced collagen density, and vascular calcification seem to contribute to stiffer arteries in CKD patients [10, 11]. It has been demonstrated that vascular stiffness may predict adverse cardiovascular outcomes [12, 13]. Current gold standard for vascular stiffness evaluation is the pulse wave velocity (PWV) which requires complex equipment and therefore is not commonly used in clinical practice [14]. Recently, a new parameter named ambulatory arterial stiffness index (AASI) was proposed for this evaluation [15, 16]. This index is derived from the regression slope of the diastolic on systolic blood pressure, using all of the readings during ambulatory blood pressure monitoring (ABPM).

Ambulatory arterial stiffness index (AASI) is a parameter obtained from ambulatory blood pressure monitoring (ABPM) that correlates with clinical endpoints. The aim of this study was to compare AASI in nondiabetic hypertensive patients with and without chronic kidney disease (CKD). Subjects with systemic arterial hypertension (SAH, \( n = 30 \)) with normal renal function, aged 40 to 75 years, were compared to hypertensive patients with CKD (\( n = 30 \)) presenting estimated glomerular filtration rate (eGFR) < 60 mL/min by MDRD formula. ABPM was carried out in all patients. In CKD group, eGFR was 35.3 ± 2.8 ml/min. The mean 24-hour systolic and diastolic blood pressure (BP) was similar in both groups. AASI was significantly higher in CKD group (0.45 ± 0.03 versus 0.37 ± 0.02, \( P < 0.05 \)), positively correlated to age (\( r = 0.38, P < 0.01 \)) and pulse pressure (\( r = 0.43, P < 0.01 \)) and negatively correlated to nocturnal BP fall (\( r = -0.28, P = 0.03 \)). These findings indicate the presence of stiffer vessels in CKD hypertensive patients.
2. Methods

A case-control study involving 60 consecutive patients with primary hypertension was carried out in our institution. Thirty patients were recruited from the CKD outpatient clinic. Hypertensive patients with CKD, aged 40 to 75 years and estimated glomerular filtration rate (eGFR) <60 mL/min by the Modification of Diet in Renal Disease (MDRD) equation [23], were included (CKD group). Other 30 patients matched by age (±2 years) and gender with the CKD patients were selected from the hypertension outpatient clinic at the same institution. These patients presented systemic arterial hypertension (SAH group) and serum creatinine less than 1 mg/dL. Exclusion criteria were diabetes mellitus, hypertriglyceridemia (>400 mg/dL), urinary albumin-to-creatinine ratio (UACR) >1000 mg/g, acute renal failure, renal replacement therapy, regular use of anti-inflammatory drugs, and history of myocardial infarction or cerebrovascular disease in the last 6 months. The local Ethics Committee has previously approved the study protocol, and all participants gave written informed consent.

2.1. Blood Pressure Measurements. Office blood pressure was obtained using an electronic device (model HEM-705CP, Omron Healthcare Inc., IL, USA) and an appropriate sized cuff. Patients were seated for 30 minutes before measurement and refrained from smoking and caffeine ingestion in this period of time. Three readings, one minute apart, were done, and the average of these measurements was defined as the patient clinic blood pressure. The patients underwent 24-hour ABPM in nondominant arm with SpaceLabs 90207 monitor (Spacelabs Inc., Redmond, WA, USA), validated by the British Hypertension Society and the Association for the Advancement of Medical Instrumentation protocol [24]. Readings were taken every 20 minutes during the day and every 30 minutes at night. The patients recorded their sleep and wake times during the monitoring. ABPM was considered adequate if >70% of measurements were successfully obtained. The percentage decline in nocturnal blood pressure was calculated as follows for systolic (SBP) and diastolic (DBP) blood pressures: percentage decline in nocturnal blood pressure = (daytime blood pressure − night-time blood pressure) / 100/daytime blood pressure. The AASI was calculated from 1 minus the regression slope of diastolic pressure on systolic blood pressure. The slope was not forced through the origin.

2.2. Blood and Urine Samples Collection. Fasting venous blood was collected from participants to measure total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), glucose, creatinine (enzymatic method), and uric acid. The low-density lipoprotein cholesterol (LDL-C) level was calculated by the Friedewald formula (8). eGFR was assessed by modified MDRD equation: eGFR = 0.741 × 175 × Cr−1.154 × age−0.203 (× 0.742 if female). C-reactive protein (nephelometry, BN II, Siemens AG Inc, Munich, Germany) and morning urinary spot albumin and creatinine (nephelometry, Immage, Beckman Coulter Inc, Fullerton, CA, USA) were also measured. The lower detection limit for C-reactive protein was 0.20 mg/L. Values for microalbuminuria were considered normal up to 30 mg/g creatinine.

2.3. Statistical Analyses. Data are presented as mean ± standard error of mean (SEM). For database management and statistical analyses, we used GraphPad Prism software, version 5.0 (GraphPad Software Inc., CA, USA). Chi-squared test (for 2 × 3 tables) or Fisher’s exact test (for 2 × 2 tables) and Student’s t-test were used to compare proportions and means, respectively. Pearson’s correlation coefficients were used to explore associations between examined continuous variables with parametric distribution. Statistical significance was determined by α-level of 0.05 on two-sided tests.

3. Results

Baseline clinical characteristics did not differ between the groups. As expected, hemoglobin was significantly lower and serum creatinine and uric acid were significantly higher in CKD group (Table 1). Mean eGFR by MDRD in the CKD group was 35.3 ± 2.8 mL/min. C-reactive protein and UACR were significantly higher in CKD group (Table 1).

The mean office and ambulatory blood pressure readings were similar in both groups (Table 2), although CKD patients needed to use more antihypertensive drugs (2.7 ± 0.2 versus 2.2 ± 0.1, P = 0.0398) to obtain blood pressure control. When CKD was compared to SAH group concerning antihypertensive treatment, there was no significant difference for diuretics (60% versus 70%), angiotensin converting enzyme inhibitors/angiotensin receptor blockers (86% versus 77%) and beta blockers (40% versus 37%). However, use of calcium channel antagonists was significantly more common in CKD patients (47% versus 23%, P < 0.01).

The mean nocturnal systolic blood pressure fall was lower than 10% in both groups (4.0 ± 1.5% in CKD versus 7.6 ± 1.1% in SAH, P = 0.0588). There were 40% of dipper
Table 1: Demographic, anthropometric, and laboratory data of hypertensive patients in both groups.

| Variable                                      | SAH group | CKD group | P value |
|-----------------------------------------------|-----------|-----------|---------|
| Age (years)                                   | 62.8 ± 1.7| 63.2 ± 1.7| 0.8786  |
| Men, n (%)                                    | 18 (60)   | 18 (60)   | 1.0000  |
| Black, n (%)                                  | 4 (13)    | 7 (23)    | 0.3251  |
| Current smokers, n (%)                        | 5 (17)    | 4 (13)    | 0.7232  |
| Previous cerebrovascular disease, n (%)       | 2 (7)     | 2 (7)     | 1.0000  |
| Dyslipidemia, n (%)                           | 14 (47)   | 13 (43)   | 0.2645  |
| BMI (kg/m²)                                   | 27.4 ± 0.8| 26.4 ± 0.8| 0.3856  |
| Waist-to-hip ratio                            | 0.93 ± 0.01| 0.92 ± 0.01| 0.6881  |
| Hemoglobin (g/dL)                             | 13.9 ± 0.2| 12.5 ± 0.2| <0.0001 |
| Glucose (mg/dL)                               | 95.8 ± 11.1| 98.7 ± 8.9| 0.2645  |
| Creatinine (mg/dL)                            | 0.82 ± 0.17| 2.26 ± 0.78| <0.0001 |
| eGFR (mL/min)                                 | 92.8 ± 4.8| 35.3 ± 2.8 | <0.0001 |
| Sodium (mg/dL)                                | 139 ± 0.4 | 137 ± 3.4 | 0.6317  |
| Potassium (mg/dL)                             | 4.3 ± 0.09| 4.8 ± 0.08| 0.0927  |
| Uric acid (mg/dL)                             | 6.0 ± 2.0 | 8.4 ± 1.8  | <0.0001 |
| Triglycerides (mg/dL)                         | 164 ± 100 | 232 ± 149 | 0.0737  |
| Total Cholesterol (mg/dL)                     | 205 ± 36  | 200 ± 41  | 0.6555  |
| LDL-cholesterol (mg/dL)                       | 120 ± 39  | 106 ± 33  | 0.1489  |
| HDL-cholesterol (mg/dL)                       | 51 ± 24   | 39 ± 10   | 0.0199  |
| C-Reactive protein (mg/L)                     | 2.6 ± 0.6 | 6.4 ± 1.7 | 0.0338  |
| UACR (mg/g)                                   | 19 ± 5    | 367 ± 90  | 0.0002  |
| LVH in ECG, n (%)                             | 1 (4)     | 4 (13)    | 0.2216  |

Data presented as mean ± SEM or n (%). SAH, systemic arterial hypertension; CKD, chronic kidney disease; BMI, body mass index; eGFR, estimated glomerular filtration rate by MDRD equation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; UACR, urinary albumin-creatinine ratio; LVH, left ventricular hypertrophy; ECG, electrocardiogram.

Table 2: Office and ambulatory blood pressure parameters of hypertensive patients with normal and impaired renal function.

| BP parameters                           | SAH group | CKD group | P value |
|-----------------------------------------|-----------|-----------|---------|
| AASI, units                             | 0.37 ± 0.02| 0.45 ± 0.03| 0.0400  |
| Office systolic BP, mmHg                | 149 ± 3   | 145 ± 4   | 0.4452  |
| Office diastolic BP, mmHg               | 87 ± 2    | 85 ± 2    | 0.5121  |
| Controlled office BP, n (%)             | 15 (50)   | 10 (33)   | 0.2949  |
| 24 h systolic BP, mmHg                  | 131 ± 3   | 133 ± 3   | 0.6172  |
| 24 h diastolic BP, mmHg                 | 81 ± 2    | 79 ± 2    | 0.6004  |
| 24 h Pulse Pressure, mmHg               | 50 ± 2    | 54 ± 2    | 0.2034  |
| Controlled 24 h BP, n (%)               | 14 (47)   | 14 (47)   | 1.0000  |
| White coat effect, n (%)                | 6 (20)    | 3 (10)    | 0.2859  |
| Daytime systolic BP, mmHg               | 134 ± 3   | 135 ± 3   | 0.8732  |
| Daytime diastolic BP, mmHg              | 83 ± 2    | 81 ± 2    | 0.5507  |
| Nocturnal systolic BP, mmHg             | 124 ± 3   | 129 ± 3   | 0.2707  |
| Nocturnal diastolic BP, mmHg            | 75 ± 2    | 74 ± 2    | 0.9644  |
| Systolic nocturnal fall, %              | 7.6 ± 1.1 | 4.0 ± 1.5 | 0.0588  |
| Diastolic nocturnal fall, %             | 10.7 ± 0.1| 8.6 ± 0.2 | 0.2945  |

Data are expressed as mean ± SEM or n (%). AASI, ambulatory arterial stiffness index; SAH, systemic arterial hypertension; CKD, chronic kidney disease; BP, blood pressure.
patients, 50% of nondipper, and 10% of reverse dipper in SAH group. On the other hand, CKD group presented 30% of dipping pattern, 40% nondipping, and 30% reverse dipping (Figure 1). Pulse pressure was not different between CKD and SAH groups (54 ± 2 versus 50 ± 2 mmHg, P = 0.20).

The AASI index was significantly higher in CKD patients when compared with SAH group (0.45 ± 0.03 versus 0.37 ± 0.02, P = 0.04). Correlation tests showed that AASI was positively related to age (r = 0.38, P < 0.01), pulse pressure (r = 0.43, P < 0.01) and inversely related to nocturnal blood pressure fall (r = −0.28, P = 0.03) (Figure 2). AASI did not correlate to UACR, serum creatinine, or eGFR. However, when eGFR was analyzed among all patients, those with eGFR less than 30 mL/min had higher AASI (Figure 3).

4. Discussion

The results of our study demonstrate that hypertensive patients with CKD presented a higher AASI when compared to those with normal renal function. Supporting the concept that AASI is a marker of arterial stiffness, Li et al. described its correlation with pulse wave velocity, central and peripheral augmentation indexes [15]. Moreover, in a cohort of 11,291 patients, Dolan et al. showed that AASI carried prognostic information, as it was a predictor of stroke and cardiac death [16]. In a Japanese study, Kikuya et al. also observed that AASI predicted cardiovascular and stroke mortality over and beyond pulse pressure [25]. Muxfeldt et al. demonstrated that AASI is a predictor of cardiovascular morbidity and mortality in 547 patients with resistant hypertension [21]. Furthermore, some research groups have already reported that AASI presents good reproducibility, with repeatability coefficients close to 60% [26, 27]. Criticizers say that this index is dependent on pulse pressure and dipping pattern and do not provide new information [28, 29]. Schillaci et al. studied 515 untreated hypertensive patients and found that AASI was strongly dependent on the degree of nocturnal blood pressure fall and only weakly related to pulse wave velocity [28]. Similar results were found by Baumann et al. with 112 German hypertensive patients [29].

Some authors have studied the relationship between AASI and renal function among hypertensive patients. Ratto et al. showed that AASI was positively related to urinary albumin excretion and negatively related to estimated creatinine clearance in a population of 168 patients with recently diagnosed hypertension and without drug treatment [30]. Mule et al. studied 142 hypertensive patients without drug treatment and with serum creatinine less than 1.5 mg/dL and demonstrated that patients with high AASI presented lower GFR [17]. This paper also suggested that AASI was a better predictor of GFR decline than 24 h pulse pressure. In 554 hypertensive patients with and without drug treatment, García-Garcia et al. observed that AASI correlates with eGFR, carotid intima-media thickness, and Cornell voltage-duration product [20].

Ageing is an important factor for arterial stiffening. Elderly people are predisposed to lose arterial elastic laminae and increase collagen deposits in vascular wall [10, 31]. This way, assuming AASI as a marker of vascular stiffness, the relationship between AASI and age is expected. Interestingly, CKD patients tend to have stiffer vessels when compared to age- and blood-pressure-matched patients with normal renal function [31, 32]. Beyond traditional risk factors, such as hypertension and dyslipidemia, uremia seems also play a role to this finding. Mineral metabolism alterations and arterial calcification are probably relevant mechanisms [10, 33]. This
may be one hypothesis to explain why AASI was higher in CKD than in SAH group despite similar office and ambulatory blood pressure measurements in the present study. Moreover, patients with the lowest eGFR (stage 4, according to the American National Kidney Foundation [4]) presented higher AASI.

Pulse pressure and nocturnal blood pressure fall are two parameters from ABPM that correlate with arterial stiffness [34, 35]. Lekakis et al. and Jerrard et al. showed that hypertensive patients with nondipper pattern presented stiffer vessels when measured by pulse wave velocity, suggesting a relationship between blunted nocturnal blood pressure fall and reduced arterial elasticity [35, 36]. These findings corroborate with our study, since nocturnal blood pressure fall and pulse pressure were correlated with AASI. Indeed, AASI was different between groups despite similar pulse pressure and dipper status. This emphasizes the importance of calculating AASI after ABPM.

The present study has limitations considering the small sample size. Moreover, it was not prospective and not focused on clinical outcomes. However, our data strongly implies the value of AASI as a noninvasive tool for hemodynamic evaluation of CKD patient and reinforces the role of ABPM in hypertensive patients with renal dysfunction. Increased AASI might be one of the pathophysiological changes observed in CKD patients before the progression to end stage renal disease. More studies are needed to support the clinical usefulness of this parameter, but we propose that the software for ABPM analysis should include AASI value as a marker of cardiovascular risk assessment in the near future.

Conflict of Interests
The authors declare that they have no conflict of interests.

Acknowledgments
This research was partially supported by the Foundation to Support Research at State of Rio de Janeiro (FAPERJ). The authors would like to thank Sergio Franco Laboratory for the measurements of serum C-reactive protein and urinary albumin and creatinine.

References
[1] E. Ritz, “Hypertension: the kidney is the culprit even in the absence of kidney disease,” Kidney International, vol. 71, no. 5, pp. 371–372, 2007.

[2] A. M. Thompson and T. G. Pickering, “The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease,” Kidney International, vol. 70, no. 6, pp. 1000–1007, 2006.

[3] D. E. Weiner, H. Tighiouart, P. C. Stark et al., “Kidney disease as a risk factor for recurrent cardiovascular disease and mortality,” American Journal of Kidney Diseases, vol. 44, no. 2, pp. 198–206, 2004.

[4] A. S. Levey, J. Coresh, K. Bolton et al., “KDQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, supplement 1, no. 2, pp. S1–S266, 2002.

[5] M. J. Sarnak, T. Greene, X. Wang et al., “The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study,” Annals of Internal Medicine, vol. 142, no. 5, pp. 342–351, 2005.

[6] T. H. Jafar, P. C. Stark, C. H. Schmid et al., “Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis,” Annals of Internal Medicine, vol. 139, no. 4, pp. 244–252, 2003.

[7] D. Ljuticand and P. Kes, “The role of arterial hypertension in the progression of non-diabetic glomerular diseases,” Nephrology Dialysis Transplantation, vol. 18, supplement 5, pp. v28–v30, 2003.

[8] J. J. Mourad, B. Pannier, J. Blacher et al., “Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension,” Kidney International, vol. 59, no. 5, pp. 1834–1841, 2001.

[9] P. Gosse and M. E. Safar, “Arterial stiffness and plasma creatinine in untreated hypertensive patients,” American Journal of Hypertension, vol. 18, no. 9, pp. 1140–1145, 2005.

[10] A. P. Guerin, B. Pannier, F. Metivier, S. J. Marchaisand, and G. M. London, “Assessment and significance of arterial stiffness in patients with chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 6, pp. 635–641, 2008.

[11] C. D. Chu, J. N. Townend, R. P. Steedsand, and C. J. Ferro, “Republished paper: arterial stiffness in chronic kidney disease: causes and consequences,” Postgraduate Medical Journal, vol. 86, no. 1019, pp. 560–566, 2010.

[12] S. Laurent, P. Boutouyrie, R. Asmar et al., “Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients,” Hypertension, vol. 37, no. 5, pp. 1236–1241, 2001.

[13] T. W. Hansen, J. A. Staessen, C. Torp-Pedersen et al., “Ambulatory arterial stiffness index predicts stroke in a general population,” Journal of Hypertension, vol. 24, no. 11, pp. 2247–2253, 2006.

[14] S. Laurent, J. Cockcroft, L. Van Bortel et al., “Expert consensus document on arterial stiffness: methodological issues and clinical applications,” European Heart Journal, vol. 27, no. 21, pp. 2588–2605, 2006.

[15] Y. Li, J. G. Wang, E. Dolan et al., “Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring,” Hypertension, vol. 47, no. 3, pp. 359–364, 2006.

[16] E. Dolan, L. Thijs, Y. Li et al., “Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the dublin outcome study,” Hypertension, vol. 47, no. 3, pp. 365–370, 2006.

[17] G. Mulè, S. Cottone, P. Cusimano et al., “Inverse relationship between ambulatory arterial stiffness index and glomerular filtration rate in arterial hypertension,” American Journal of Hypertension, vol. 21, no. 1, pp. 35–40, 2008.

[18] G. Leoncini, E. Ratto, F. Viazzi et al., “Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension,” Hypertension, vol. 48, no. 3, pp. 397–403, 2006.

[19] H. Triantafyllidi, S. Tzortzis, J. Lekakis et al., “Association of target organ damage with three arterial stiffness indexes according to blood pressure dipping status in untreated hypertensive patients,” American Journal of Hypertension, vol. 23, no. 12, pp. 1265–1272, 2010.

[20] A. García-García, M. A. Gomez-Marcos, J. I. Recio-Rodriguez et al., “Relationship between ambulatory arterial stiffness index and subclinical target organ damage in hypertensive
patients,” *Hypertension Research*, vol. 34, no. 2, pp. 180–186, 2010.

[21] E. S. Muxfeldt, C. R. L. Cardoso, V. B. Dias, A. C. M. Nascimento, and G. F. Salles, “Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension,” *Journal of Hypertension*, vol. 28, no. 7, pp. 1547–1553, 2010.

[22] M. Kikuya, J. A. Staessen, T. Ohkubo et al., “How many measurements are needed to provide reliable information in terms of the ambulatory arterial stiffness index the Ohasama study,” *Hypertension Research*, vol. 34, no. 3, pp. 314–318, 2011.

[23] A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogersand, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group,” *Annals of Internal Medicine*, vol. 130, no. 6, pp. 461–470, 1999.

[24] E. O’Brien, N. Atkins, and J. Staessen, “State of the market: a review of ambulatory blood pressure monitoring devices,” *Hypertension*, vol. 26, no. 5, pp. 835–842, 1995.

[25] M. Kikuya, J. A. Staessen, T. Ohkubo et al., “Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama, Japan,” *Stroke*, vol. 38, no. 4, pp. 1161–1166, 2007.

[26] G. S. Stergiou, A. Kollias, V. C. Rarra, and L. G. Roussias, “Ambulatory arterial stiffness index: reproducibility of different definitions,” *American Journal of Hypertension*, vol. 23, no. 2, pp. 129–134, 2010.

[27] D. G. Dechering, M. S. van der Steen, A. Adiyaman et al., “Reproducibility of the ambulatory arterial stiffness index in hypertensive patients,” *Journal of Hypertension*, vol. 26, no. 10, pp. 1993–2000, 2008.

[28] G. Schillaci, G. Parati, V. C. Rarra, and L. G. Roussias, “Ambulatory arterial stiffness index: reproducibility of different definitions,” *American Journal of Hypertension*, vol. 23, no. 2, pp. 129–134, 2010.

[29] A. P. Guerin, B. Pannier, S. J. Marchaisand, and G. M. London, “Arterial structure and function in end-stage renal disease,” *Current Hypertension Reports*, vol. 10, no. 2, pp. 107–111, 2008.

[30] F. H. Verbeke, M. Agharazii, P. Boutouyrie, B. Pannier, A. P. Guérin, and G. M. London, “Local shear stress and brachial artery functions in end-stage renal disease,” *Journal of the American Society of Nephrology*, vol. 18, no. 2, pp. 621–628, 2007.

[31] G. M. London, A. P. Guérin, F. H. Verbeke et al., “Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency,” *Journal of the American Society of Nephrology*, vol. 18, no. 2, pp. 613–620, 2007.

[32] H. Y. Lee and B. H. Oh, “Aging and arterial stiffness,” *Circulation Journal*, vol. 74, no. 11, pp. 2257–2262, 2010.

[33] J. P. Lekakis, N. A. Zakopoulos, A. D. Protogerou et al., “Arterial stiffness assessed by pulse wave analysis in essential hypertension: relation to 24-h blood pressure profile,” *International Journal of Cardiology*, vol. 102, no. 3, pp. 391–395, 2005.